Project Determination

# **2024 Spring Clinical Laboratory Partners Forum Meeting**

|  |  |
| --- | --- |
| **Project ID:** | 0900f3eb82344243 |
| **Accession #:** | CLSR-DLS-3/22/24-44243 |
| **Project Contact:** | Latesha Whisby |
| **Organization:** | CLSR/DLS |
| **Status:** | Pending Clearance |
| **Intended Use:** | Project Determination |
| **Estimated Start Date:** | 03/22/24 |
| **Estimated Completion Date:**  | 04/05/24 |
| **CDC/ATSDR HRPO/IRB Protocol#:**  |  |
| **OMB Control#:**  | 0920-1050 |
|  |  |

|  |
| --- |
| Description |
| Priority |
| Standard |
| Date Needed |
| 04/05/24 |
| Determination Start Date |
| 03/22/24 |
| Description |
| This information collection is being conducted to examine the effectiveness of the May 22, 2024, Meeting for the Clinical Laboratory Partners Forum (CLPF), a group of laboratory professional, standard-setting, and accreditation organizations that meets periodically to share information and focus on clinical and public health laboratory partnerships, particularly as related to preparedness and response, laboratory workforce, biosafety, and patient safety and diagnostic excellence. The Division of Laboratory Systems at the Centers for Disease Control and Prevention, who periodically convenes this group or organizations, is seeking feedback from participants to assess the effectiveness and relevance of the May 22, 2024, meeting, in an effort to ensure that meetings of this group are managed effectively and focused on issues of current importance to clinical and public health laboratories. |
| IMS/CIO/Epi-Aid/Lab-Aid/Chemical Exposure Submission |
| No |
| IMS Activation Name |
| Not selected |
| Select the primary priority of the project |
| Not selected |
| Select the secondary priority(s) of the project |
| Not selected |
| Select the task force associated with the response |
| Not selected |
| CIO Emergency Response Name |
| Not selected |
| Epi-Aid Name |
| Not selected |
| Lab-Aid Name |
| Not selected |
| Assessment of Chemical Exposure Name |
| Not selected |
| Goals/Purpose |
| DLS is seeking feedback from participants to assess the effectiveness and relevance of the May 22, 2024, meeting in an effort to ensure that the meetings of this group are managed effectively and focused on issues of current importance to clinical and public health laboratories. |
| Objective |
| This survey will collect participant feedback to assess 1) How useful CLPF is to participants, 2) the effectiveness of the topics and format, and 3) the planning and organization of future meetings. |
| Does your project measure health disparities among populations/groups experiencing social, economic, geographic, and/or environmental disadvantages? |
| No |
| Does your project investigate underlying contributors to health inequities among populations/groups experiencing social, economic, geographic, and/or environmental disadvantages? |
| No |
| Does your project propose, implement, or evaluate an action to move towards eliminating health inequities? |
| Yes |
| Activities or Tasks |
| New Collection of Information, Data, or Biospecimens |
| Target Population to be Included/Represented |
| Other-Clinical laboratory professionals |
| Tags/Keywords |
| Clinical Laboratory Services |
| CDC's Role |
| Activity originated and designed by CDC staff, or conducted at the specific request of CDC, or CDC staff will approve study design and data collection as a condition of any funding provided |
| Method Categories |
| Survey |
| Methods |
| Quantitative and qualitative data collection using an online survey will be conducted with clinical and public health laboratory professionals. Thematic analysis will be performed for the data collected to inform the effectiveness and relevance of the 2024 Clinical Laboratory Partners Forum. No biospecimens will be collected. |
| Collection of Info, Data, or Bio specimens |
| Quantitative and qualitative data will be collected using an online survey. No personally identifiable information will be collected. Descriptive and thematic analysis will be conducted. All results will be in aggregate form, without attribution to any person, to preserve the anonymity of respondents. |
| Expected Use of Findings/Results and their impact |
| The end results will be a comprehensive report that summarizes survey data findings and key takeaways. DLS will conduct quantitative and qualitative analysis to describe findings and generate themes based on collected data. DLS staff will receive briefings on the report, which will be used to inform future planning and organization strategies for CLPF. |
| Could Individuals potentially be identified based on Information Collected? |
| No |

| ****Funding**** |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Funding Type | Funding Title | Funding # | Original Fiscal Year | # of Years of Award | Budget Amount |

| ****HSC Review**** |
| --- |
| HSC Attributes |
| Program Evaluation |
| Yes |
| Additional Ethical Considerations |
| The division plans to do an anonymous survey of the participants of the May 22, 2024 Clinical Laboratory Partners Forum (CLPF) to examine the usefulness and effectiveness of this CDC organized activity. No PII will be collected. This information collection project is not intended to develop or contribute to generalizable knowledge so does not meet the definition of research as defined under 45 CFR 46.102(l). |

| ****Regulation and Policy**** |
| --- |
| Do you anticipate this project will need IRB review by the CDC IRB, NIOSH IRB, or through reliance on an external IRB? |
| No |

| Will you be working with an outside Organization or Institution? No |
| --- |

| ****Institutions**** |  |  |  |  |
| --- | --- | --- | --- | --- |
| Institution | FWA # | FWA Exp. Date | Funding | Funding Restriction Amount |

| Institution | Funding Restriction Percentage | Funding Restriction Reason | Funding Restriction has been lifted |
| --- | --- | --- | --- |

| Institution | Institution Role(s) | Institution Project Title | Institution Project Tracking # | Prime Institution |
| --- | --- | --- | --- | --- |

| Institution | Regulatory Coverage | IRB Review Status |
| --- | --- | --- |

| Institution | Registered IRB | IRB Registration Exp. Date | IRB Approval Status |
| --- | --- | --- | --- |

| Institution | IRB Approval Date | IRB Approval Exp. Date | Relying Institution IRB |
| --- | --- | --- | --- |

| ****Staff**** |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Staff Member | SIQT Exp. Date | Citi Biomedical Exp. Date | Citi Social and Behavioral Exp. Date | Citi Good Clinical Exp. Date | Staff Role | Email | Phone # | Organization/Institution |
| QiZheng | 08/30/2026 |  |  |  | Project Coordinator | qaz0@cdc.gov | 404-498-6258 | DIVISION OF LABORATORY SYSTEMS |

|  |  |
| --- | --- |
| ****DMP**** |  |
| ****Proposed Data Collection Start Date**** | **05/22/24** |
| ****Proposed Data Collection End Date**** | **06/14/24** |
| ****Proposed Public Access Level**** | **Non-Public** |
| ****Reason for not Releasing the Data**** | **Other- Data will be for CDC and DLS internal use to inform the meeting's effectiveness.** |
| ****Public Access justification**** | **Information will be used by CDC and DLS internally and will not be released publicly.** |
| ****How Access Will Be Provided for Data**** | **The anonymous, deidentified data will be retained on DLS internal SharePoint site so that only authorized staff are permitted access. The data will be stored with adequate security measures in compliance with CDC requirements and adherence with federal records requirements.** |
| ****Plans for archival and long-term preservation of the data**** | **Plans for Archival and Long-term Preservation of the Data** |

| ****Spatiality (Geographic Location)**** |  |  |
| --- | --- | --- |
| Country | State/Province | County/Region |

| ****Determinations**** |
| --- |
| Determination | Justification | Completed | Entered By & Role |
| HSC: Does NOT Require HRPO Review | Not Research / Other*45 CFR 46.102(l)*Program Evaluation | 03/29/24 | Leaumont\_Collette (chf3) CIO HSC |
| PRA: PRA Applies |  | 03/29/24 | Leaumont\_Collette (chf3) OMB/PRA |